South Dakota Election 2024: Statement on Amendment F
Statement from Vote No on F Committee:
Related Articles
61 Insights into interferons (IFN)-myeloid cell crosstalk: an analysis of E3611 testing ipilimumab alone or in combination with IFN-α in advanced melanoma
Background IFNs could reprogram immunosuppressive myelopoiesis, induce accumulation of APCs with capacity to prime anti-tumor immunity. IFN-α favors a Th1 shift in immunity and concurrent…
Peer Review Publications in Oncology: Episode 4
Website: https://www.onclive.comTwitter: https://twitter.com/OncLiveFacebook: https://www.facebook.com/OncLive/LinkedIn: https://www.linkedin.com/company/onc…
William Gradishar, MD, on Advances in Endocrine Therapeutic Options for Patients With ER-Positive, HER2-Negative Breast Cancer
William Gradishar, MD, discusses advances in endocrine therapeutic options for patients with estrogen receptor–positive, HER2-negative breast cancer, in follow-up to his presentation at the Lynn…
450 Pooled analysis of efficacy outcomes from early-phase trials of tumor infiltrating lymphocyte therapy in advanced melanoma
Background Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) represents a promising strategy for the treatment of patients with advanced melanoma (MEL). In this study…
Extended Lymphadenectomy Fails to Improve Survival Outcomes for Patients With Muscle-Invasive Bladder Cancer
Results from the phase 2 SWOG S1011 study demonstrated that extended lymphadenectomy failed to improve survival compared to standard lymphadenectomy among patients with localized muscle-invasive…
Zongertinib Research Could Represent Next Wave in HER2-Mutated NSCLC Management
Christina S. Baik, MD, MS, discusses the types of HER2 testing that should be performed in NSCLC and the design of the phase 3 Beamion…
‘EL LOTO AZUL’ · ED. FACSIMIL EN B/N COLOREADA · EN FRANCÉS
‘EL LOTO AZUL’ · ED. FACSIMIL EN B/N COLOREADA · EN FRANCÉS
451 CD40L-4–1BB can stimulate tumor infiltrating lymphocyte ex vivo expansion from melanoma core biopsies
Background Tumor-infiltrating lymphocyte (TIL) expansion ex vivo is currently performed from surgically excised tumors in culture media containing Interleukin-2 (IL-2). Targeting antigen-presenting cells through CD40…
Current Practices in B7-H3 Testing
Joshua K. Sabari, MD, discusses whether individual B7-H3 analysis is available at his institution, noting that, if it is, he obtains IHC for both PD-L1…
NCI Trials for November 2024 – The Cancer Letter
The National Cancer Institute approved the following clinical research studies last month. To access this subscriber-only content please log in or subscribe.If your institution…
